COMMUNIQUÉS West-GlobeNewswire
-
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
03/03/2026 -
BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT)
03/03/2026 -
COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
03/03/2026 -
Daxor Corporation Reports 2025 Fiscal Year Results: Operating Revenue Up 45%, Net Asset Value Rises to $9.07 Per Share
03/03/2026 -
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
03/03/2026 -
Prenetics Executives Execute Second Consecutive Round of Post-Earnings Open Market Share Purchases of $1.3 Million— Cumulative Personal Investment Across Both Rounds Reaches $2.7 Million
03/03/2026 -
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma
03/03/2026 -
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
03/03/2026 -
Immix Biopharma to Participate in Upcoming Investor Conferences
03/03/2026 -
INVO Fertility’s Wisconsin Clinic Joins Progyny Network
03/03/2026 -
Propanc Biopharma’s Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models
03/03/2026 -
Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call
03/03/2026 -
rYojbaba Announces $3.2 Million Comprehensive Global Labor Support and Union Infrastructure Development Agreement with International Labor Union
03/03/2026 -
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference
03/03/2026 -
Vericel to Present at Multiple Upcoming Investor Conferences
03/03/2026 -
THC Therapeutics, Inc. Announces Filing of 10-K and Provides Corporate Update
03/03/2026 -
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
03/03/2026 -
TOMI Environmental Solutions Appoints Total Clean Air as Preferred European Partner for SteraMist iHP Decontamination Technology
03/03/2026 -
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
03/03/2026
Pages